Navigation Links
Angiotech appoints Hank McKinnell to its Board of Directors
Date:5/13/2008

VANCOUVER, May 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Dr. Hank McKinnell to its Board of Directors.

Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and the Lead Director of the Board of Directors of Moody's Corporation.

"We are honoured that Dr. McKinnell has agreed to join our Board of Directors," said Dr. William Hunter, President and CEO of Angiotech. "With his history and experience in many roles at Pfizer, including as Chairman and CEO, Dr. McKinnell brings the deep industry knowledge and extraordinary leadership qualities that we will need to facilitate our continued evolution into a significant, multinational, operating business in the life sciences sector."

Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years, held positions of increasing responsibility around the world, including service as President of Pfizer Asia. In 1984, Dr. McKinnell relocated to New York, where he served as Vice President-Strategic Planning, Chief Financial Officer, President-Pfizer Medical Device Group, President-Pfizer Pharmaceuticals Group, and President and Chief Operating Officer. He was named Chairman and Chief Executive officer in 2001 and served in this role until his retirement in the second half of 2006.

Dr. McKinnell is the Chairman Emeritus of the Business Roundtable, an association of the CEOs of America's largest companies, the Pharmaceutical Research Manufacturers A
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Angiotech to participate in Bank of America Health Care Conference
2. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
3. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
4. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
5. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
6. Angiotech announces director resignation
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
9. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
10. Angiotech to participate in Lehman Brothers Healthcare Conference
11. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...nd LOS ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall...etin Board: CYXN; ,China Yongxin,Pharmaceuticals, ...utor and,retailer of pharmaceuticals in Northeaste...tion for distribution of medicines on the Essentia...ently formalized the nation,s Essential Drug,List ...
(Date:11/30/2009)...Nov. 30 Exiqon A/S (NASDAQ OMX Cop...edical School ICCB-Longwood Screening Facility (IC...Center of Excellence. ICCB-L supports investigato...tals and institutions, for high-throughput screeni...roRNAs are a novel class of small, non-coding RNA ...
(Date:11/28/2009)... National Advisory Committee on Climate Change (NA...C) Project in collaboration with the Vanuatu Meteo...land have generated preliminary climate change and...und for the country’s SNC reporting to the U...ge (UNFCCC). , Port Vila...
(Date:11/25/2009)...25 Research Triangle Park-based Cn...gle-treatment water purification system NanoPure(T...sh, Minister of Rural Water Supply, Hon. Minister ...ay. Initial tests, performed at Indian Institute o...rity of the drinking water available in India cont...
Breaking Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
...team including scientists from the London Centre f...n the journal Proceedings of the National Academy ...cts of quantum mechanics in a simple magnet. The i...onventional tool of material science neutron beam...actors can be used to produce images of the ghost...
...24 New Brunswick,Scientific Co., Inc. ("NBS") (Na...nnounced today the completion of the previously an...ired NBS for approximately $110,million in an all-... was,approved by NBS, shareholders at a special me...entitled to receive $11.50 per share in cash. NBS...
... to Advance Biologics Strategy Through Targeted ...CETON, N.J. and WALTHAM, Mass., Sept. 24 ,Bristol-... Therapeutics,announced today the companies have s...yers Squibb will acquire privately held Adnexus,Th...f biologics called,Adnectins(TM). The acquisition ...
Other Biology Technology:Imaging quantum entanglement 2New Brunswick Scientific Completes Merger Transaction with Eppendorf 2Bristol-Myers Squibb to Acquire Adnexus Therapeutics 2Bristol-Myers Squibb to Acquire Adnexus Therapeutics 3Bristol-Myers Squibb to Acquire Adnexus Therapeutics 4Bristol-Myers Squibb to Acquire Adnexus Therapeutics 5
(Date:11/26/2009)...IDGE, Mass. (November 26, 2009) Whitehead researc...or human cells to pinpoint specific genes and prot...n Science . , In most human cell cultures genes... father and one from the mother. Gene inactivation... one copy is inactivated, the second copy usually ...
(Date:11/26/2009)...(methicillin-resistant Staphylococcus Aureus ) an...ation as low-temperature plasma prototype devices ... unfailing bactericidal cocktails. , Two prototy...disinfection of healthy skin (e.g. hands and feet)... pose a lethal threat; and another to shoot bacter...
(Date:11/25/2009)...in, a hormone produced in the stomach, may be used...of Parkinson,s disease, Yale School of Medicine re...issue of the Journal of Neuroscience . , Parkin...ine neurons in an area of the midbrain known as th...ine production. Reduced production of dopamine in...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Retail Health Clinics The Real Story 59443 1Retail Health Clinics The Real Story 59443 2Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 1Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 2Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 3Pajama Program Launches 2009 2010 Awareness 26amp 3B Fundraising Campaign 3A A BETTER BEDTIME 59441 4
...European Lung Cancer Conference, jointly organized...O) and the International Association for the Study...hlight emerging evidence that common viruses may c...xperts agree that smoking is by far the most impor...pment. But other factors can play a role in some c...
...ngs the first signs of harmful algae in New Englan...s Hole Oceanographic Institution (WHOI) and North ... for a potentially big bloom. , A combination of...ecipitation have set the stage for a harmful algal...ccording to researchers from WHOI and NC State. Th...
...medical issues is the development of techniques th... published on April 24, 2008 in the journal Vaccin...b, Inc. has proposed a new technology for anti-vir...jor elements. First, each vaccine antigen should b...n the organisms cells by an intracellular chopping...
Other Biology News:Viruses may play a role in lung cancer development 2In computer models and observations, researchers see potential for significant 'red tide' season 2In computer models and observations, researchers see potential for significant 'red tide' season 3New technology for boosting vaccine efficiency 2New technology for boosting vaccine efficiency 3
Newborn Calf Serum - 100mL from GeneTex
Newborn Calf Serum - 100mL from Biomeda Corporation
TE Buffer from EPICENTRE Biotechnologies
Non-Receptor Tyrosine Kinase Sampler Kit from BD Biosciences Pharmingen
Biology Products: